Celebrating 30 years of helping you give wisely
America's most independent,
assertive charity watchdog
Top Rated

Ovarian Cancer Research Alliance

CharityWatch report issued
March 2022

Top-Rated Charity
A-
CharityWatch Grade
Our independent grade based
on a number of factors.
 
77%
Program Percentage
Amount spent on programs
relative to overhead.
 
$18
Cost to Raise $100
Amount spent to raise
$100 of contributions.

Contact Information

Ovarian Cancer Research Alliance
14 Pennsylvania Plaza
Suite 2110
New York, NY 10122

Other Names

Ovarian Cancer National Alliance
Ovarian Cancer Research Fund
Ovarian Cancer Research Fund Alliance

Tax Status

501(c)3

Stated Mission

To cure ovarian cancer, advocate for patients, and support survivors.

View similar charities
Charity  
American Breast Cancer Foundation  
American Cancer Society  
American Institute for Cancer Research  
Avon Products Foundation  
Breast Cancer Charities of America (DISSOLVED)  
Breast Cancer Outreach Foundation (DISSOLVED)  
Breast Cancer Prevention Partners  
Breast Cancer Research Foundation  
Breast Cancer Society (DISSOLVED)  
Cancer Fund of America (DISSOLVED)  
Cancer Recovery Foundation International  
Cancer Research Institute  
Cancer Survivors' Fund  
CancerCare  
Childhood Leukemia Foundation  
Children's Cancer Fund of America (DISSOLVED)  
Children's Cancer Recovery Foundation (DISSOLVED)  
Children's Cancer Research Fund  
Children's Leukemia Research Association  
CureSearch for Children's Cancer  
Damon Runyon Cancer Research Foundation  
Dana-Farber Cancer Institute  
Entertainment Industry Foundation / Stand Up To Cancer  
Good Charity (DISSOLVED)  
Leukemia & Lymphoma Society  
Livestrong Foundation  
Memorial Sloan Kettering Cancer Center  
Multiple Myeloma Research Foundation  
National Breast Cancer Coalition Fund  
National Breast Cancer Foundation  
National Cancer Assistance Foundation  
National Cancer Center  
National Cancer Coalition (DISSOLVED)  
National Children's Cancer Society  
National Children's Leukemia Foundation (DISSOLVED)  
National Foundation for Cancer Research  
Pancreatic Cancer Action Network  
Prevent Cancer Foundation  
Prostate Cancer Foundation  
St. Jude Children's Research Hospital  
Susan G. Komen Breast Cancer Foundation  
United Breast Cancer Foundation  
United Cancer Support Foundation  
Walker Cancer Research Institute  
Woman to Woman Breast Cancer Foundation (DISSOLVED)  
Data based on Fiscal Year Ended 12/31/2020

Program Percentage: 77%

The percentage of Ovarian Cancer Research Alliance's cash budget it spends on programs relative to overhead (fundraising, management, and general expenses).

$8,300,000

Calculated Total Expenses

(rounded)

 

Cost to Raise $100: $18

How many dollars Ovarian Cancer Research Alliance spends on fundraising to raise each $100 of contributions.

$5,800,000

Calculated Total Contributions

(rounded)

Government Funding

0% to 24%

Percentage of cash revenue
coming from government sources

 

Financial Documents

Entity Document Type Tax ID
Ovarian Cancer Research Alliance IRS Form 990 13-3806788
Ovarian Cancer Research Alliance Audited Consolidated Financial Statements multiple
Entity: Ovarian Cancer Research Alliance
Document Type: IRS Form 990
Tax ID: 13-3806788
Entity: Ovarian Cancer Research Alliance
Document Type: Audited Consolidated Financial Statements
Tax ID: multiple

Governance & Transparency

CharityWatch evaluates certain criteria related to a charity's Governance and Transparency. Donors may want to consider a charity's willingness to be open and transparent with CharityWatch to be a good litmus test for determining its commitment to public accountability.
This charity is Top-Rated
What does it mean to be Top-Rated?
 
Ovarian Cancer Research Alliance
meets governance benchmarks.
 
Ovarian Cancer Research Alliance
meets transparency benchmarks.
Transparency
Provides Financial Information
Audit Accessibility
Governance: Policies
Reports regularly & consistently monitoring & enforcing compliance with a written Conflict of Interest Policy
Reports required, annual disclosure by officers, directors, and key staff of interests that could give rise to conflicts
Reports having a written Whistleblower Policy
Reports having a written Document Retention and Destruction Policy
Governance: Financials
Reports providing copy of tax form to all board members prior to filing it with IRS
Reports that financial statements were audited by an independent accountant
Governance: Board of Directors
Reports at least 5 voting board members
51% or more of voting board members reported as independent
Reports documenting minutes of board and board committee meetings
Privacy Policy
Privacy Policy No Sharing  

  Name Title Compensation
1 Audra L. Moran President/CEO $310,215
2 Jonathan Zeidman VP, Development $183,681
3 Bibi Ali VP, Finance $164,779
1
Name: Audra L. Moran
Title: President/CEO
Compensation: $310,215
2
Name: Jonathan Zeidman
Title: VP, Development
Compensation: $183,681
3
Name: Bibi Ali
Title: VP, Finance
Compensation: $164,779

CharityWatch Analysts perform an in-depth analysis of charities' audited financial statements and IRS tax filings, and often review other documents such as state filings, annual reports, and fundraising contracts during their evaluations. Below are select notes that CharityWatch believes may be of interest to donors.

According to the Ovarian Cancer Research Alliance consolidated audit of December 31, 2020 (Note 1, Nature of Operations):

"The Ovarian Cancer Research Fund, Inc. ('OCRF') D/B/A Ovarian Cancer Research Alliance ('OCRA') is a corporation which was organized in the State of New York as a not-for-profit entity on December 8, 1994. OCRA executed a D/B/A on October 3, 2018 to assume the name Ovarian Cancer Research Alliance. OCRA previously operated as the Ovarian Cancer Research Fund Alliance ('OCRFA'), which name was adopted on January 1, 2016, the date on which the operations of the Ovarian Cancer National Alliance ('OCNA') were consolidated with OCRF."

According to the Ovarian Cancer Research Alliance (OCRA) consolidated audit of December 31, 2020 (Note 2 re: Contributed Services), OCRA received in-kind "contributed services for advertising services and professional fees that were utilized principally in OCRA's program operations" during 2020 on which it placed a total value of $599,310.

[Note: CharityWatch generally excludes the value of in-kind (non-cash) donations of goods and services from its calculations of Program % and Cost to Raise $100. More information on how grades are calculated and the treatment of in-kind donations can be found on the Our Process page.]

According to the Ovarian Cancer Research Alliance consolidated audit of December 31, 2020 (Note 3, Concentrations of Credit Risk):

"One donor represents approximately 12% of contribution revenue for each of the years ended December 31, 2020 and 2019."

According to the Ovarian Cancer Research Alliance (OCRA) consolidated audit of December 31, 2020 (Note 6, Note Payable – Paycheck Protection Program):

"In April 2020, OCRA entered into a Paycheck Protection Program Term Note (the 'PPP Note') with Chase Bank in the amount of $402,581. The PPP Note was issued to OCRA pursuant to the Coronavirus, Aid, Relief, and Economic Security Act's (the 'CARES Act')...Paycheck Protection Program (the 'Program'). Under the Program, all or a portion of the PPP Note may be forgiven in accordance with the Program requirements. OCRA has used all of the proceeds of the PPP Note to pay its qualified expenses...and substantially met all conditions. Therefore, in June 2021, OCRA submitted its application for loan forgiveness.

"On July 6, 2021, the forgiveness of the $402,581 loan under the Program was approved and is shown in the [audited] consolidated statements of activities as 'Grants – government'.

"Consequently, OCRA has elected to recognize the entire loan balance as income... Under this [accounting standards guidance], the PPP Note forgiveness is dependent on meeting certain conditions and would be considered a conditional contribution. Conditional contributions are recognized as income when the conditions on which they depend are met."

According to the Ovarian Cancer Research Alliance (OCRA) consolidated audit of December 31, 2020 (Note 12, Subsequent Events):

"Subsequent to year end, in March 2021, OCRA was eligible and entered into an additional PPP [Paycheck Protection Program] Note with Chase Bank in the amount of $403,500. This note has the same terms as described in Note 6 [cited separately, above].

"OCRA believes that it is in compliance with the Program requirements, and it expects to receive full forgiveness of the additional PPP Note."


Related External Articles